170 related articles for article (PubMed ID: 23591180)
1. Efficacy and safety of urethral de-obstruction in boys with overactive bladder complaints.
de Jong TP; Kuijper CF; Chrzan R; Dik P; Klijn AJ; Vijverberg MA
J Pediatr Urol; 2013 Dec; 9(6 Pt B):1072-6. PubMed ID: 23591180
[TBL] [Abstract][Full Text] [Related]
2. Transurethral incision of congenital obstructive lesions in the posterior urethra in boys and its effect on urinary incontinence and urodynamic study.
Nakamura S; Kawai S; Kubo T; Kihara T; Mori K; Nakai H
BJU Int; 2011 Apr; 107(8):1304-11. PubMed ID: 20804485
[TBL] [Abstract][Full Text] [Related]
3. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of conservative treatment versus low threshold endoscopic desobstruction on urine incontinence and urgency in boys with persistent overactive bladder symptoms: A cohort study.
Hennus PML; van den Hoek J; Hoes AW; Groenwold RHH; Bosch JLR; de Jong TPVM; de Kort LMO
Neurourol Urodyn; 2017 Sep; 36(7):1924-1929. PubMed ID: 28139859
[TBL] [Abstract][Full Text] [Related]
5. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F
J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761
[TBL] [Abstract][Full Text] [Related]
6. Late urodynamic findings after treating traumatic rupture of the posterior urethra in boys.
Otgün I; Karnak I; Senocak ME; Tanyel FC; Ciftci AO; Büyükpamukçu N
BJU Int; 2006 Feb; 97(2):367-70. PubMed ID: 16430649
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
8. Solifenacin for therapy resistant overactive bladder.
Hoebeke P; De Pooter J; De Caestecker K; Raes A; Dehoorne J; Van Laecke E; Vande Walle J
J Urol; 2009 Oct; 182(4 Suppl):2040-4. PubMed ID: 19695608
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
11. Recurrence and complications after transperineal bulboprostatic anastomosis for posterior urethral strictures resulting from pelvic fracture: a retrospective study from a urethral referral centre.
Fu Q; Zhang J; Sa YL; Jin SB; Xu YM
BJU Int; 2013 Aug; 112(4):E358-63. PubMed ID: 23773274
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron for overactive bladder syndrome.
Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
[TBL] [Abstract][Full Text] [Related]
13. Complete repair of bladder exstrophy in boys: can hypospadias be avoided?
El-Sherbiny MT; Hafez AT
Eur Urol; 2005 May; 47(5):691-4. PubMed ID: 15826764
[TBL] [Abstract][Full Text] [Related]
14. Retropubic urethrolysis of colposuspension: does it improve voiding and overactive bladder symptoms?
Basu M; Duckett JR; Papanikolaou N
J Obstet Gynaecol; 2008 Nov; 28(8):783-6. PubMed ID: 19085544
[TBL] [Abstract][Full Text] [Related]
15. No single reason behind adult lower urinary tract symptoms in patients with posterior urethral valves.
Jalkanen J; Heikkilä J; Taskinen S
Scand J Urol; 2019; 53(2-3):166-170. PubMed ID: 31006310
[No Abstract] [Full Text] [Related]
16. Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement.
Jahromi MS; Engle K; Furlong D; Guevara Méndez A; Gomez CS
Neurourol Urodyn; 2020 Jun; 39(5):1489-1493. PubMed ID: 32339308
[TBL] [Abstract][Full Text] [Related]
17. Oxybutynin for diagnosis of infravesical obstruction in boys with urinary incontinence.
de Kort LM; Klijn AJ; Dik P; Uiterwaal CS; de Jong TP
Urology; 2003 Jul; 62(1):127-30; discussion 130-1. PubMed ID: 12837438
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
20. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
